$3.54
-0.05-1.39%
At close: Dec 16, 4:00 PM EST
$3.54
N/A
After Hours: 5:59 PM EST
Comments
Loading...
Ironwood Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:IRWD | Benzinga
Ironwood Pharmaceuticals Inc has a consensus price target of $9.96 based on the ratings of 7 analysts. The high is $22 issued by JMP Securities on September 28, 2023. The low is $0.7 issued by Jefferies on April 15, 2025. The 3 most-recent analyst ratings were released by Wells Fargo, Wells Fargo, and Jefferies on November 11, 2025, April 15, 2025, and April 15, 2025, respectively. With an average price target of $1.57 between Wells Fargo, Wells Fargo, and Jefferies, there's an implied -54.85% downside for Ironwood Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Jefferies
Leerink Partners
JMP Securities
Craig-Hallum
1calculated from analyst ratings
Analyst Ratings for Ironwood Pharmaceuticals
FAQ
What is the target price for Ironwood Pharmaceuticals (IRWD) stock?
The latest price target for Ironwood Pharmaceuticals (NASDAQ:IRWD) was reported by Wells Fargo on November 11, 2025. The analyst firm set a price target for $3.00 expecting IRWD to fall to within 12 months (a possible -15.25% downside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ironwood Pharmaceuticals (IRWD)?
The latest analyst rating for Ironwood Pharmaceuticals (NASDAQ:IRWD) was provided by Wells Fargo, and Ironwood Pharmaceuticals maintained their equal-weight rating.
When was the last upgrade for Ironwood Pharmaceuticals (IRWD)?
There is no last upgrade for Ironwood Pharmaceuticals
When was the last downgrade for Ironwood Pharmaceuticals (IRWD)?
The last downgrade for Ironwood Pharmaceuticals Inc happened on April 15, 2025 when Wells Fargo changed their price target from $7 to $1 for Ironwood Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Ironwood Pharmaceuticals (IRWD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ironwood Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ironwood Pharmaceuticals was filed on November 11, 2025 so you should expect the next rating to be made available sometime around November 11, 2026.
Is the Analyst Rating Ironwood Pharmaceuticals (IRWD) correct?
While ratings are subjective and will change, the latest Ironwood Pharmaceuticals (IRWD) rating was a maintained with a price target of $1.00 to $3.00. The current price Ironwood Pharmaceuticals (IRWD) is trading at is $3.54, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
